Edition:
United States

Clementia Pharmaceuticals Inc (CMTA.OQ)

CMTA.OQ on NASDAQ Stock Exchange Global Select Market

13.23USD
23 Feb 2018
Change (% chg)

$-0.70 (-5.03%)
Prev Close
$13.93
Open
$13.83
Day's High
$13.94
Day's Low
$13.23
Volume
16,637
Avg. Vol
15,290
52-wk High
$20.12
52-wk Low
$11.77

Chart for

About

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and... (more)

Overall

Beta: --
Market Cap(Mil.): $392.62
Shares Outstanding(Mil.): 29.68
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Clementia Initiates Pivotal Phase 3 MOVE Trial For Palovarotene

* CLEMENTIA INITIATES PIVOTAL PHASE 3 MOVE TRIAL FOR PALOVAROTENE IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

Dec 12 2017

BRIEF-Clementia Pharmaceuticals qtrly loss per share ‍$1.83​

* Clementia Pharmaceuticals Inc - qtrly loss per share ‍$1.83​

Nov 13 2017

Earnings vs. Estimates